Provider file · corrected on-record pricing

Henry Meds: the corrected numbers — file and status

The 2026 correction that named this site’s method: widely-remembered “$149” pricing re-verified to $297/month semaglutide and $449/month tirzepatide month-to-month, with the advertised ~$197 lane requiring a ~$2,364 prepay flagged non-refundable in captured terms (taxonomy; how drift happens). Oral lanes $179–$249 as listed. Structure: month-to-month exit exists at the M2M price; exit risk concentrates in the prepay. Consumer-signal note: the company’s BBB profile showed an F rating when last checked — a datapoint to weigh, not a verdict. Figures dated 2026-08-17, on-record tier; full checkout audit queued. External: henrymeds.com.